Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Acalabrutinib is an oral, highly selective BTK inhibitor that allows for twice-daily dosing due to its selectivity....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Byrd, John C., Wierda, William G., Schuh, Anna, Devereux, Stephen, Chaves, Jorge M., Brown, Jennifer R., Hillmen, Peter, Martin, Peter, Awan, Farrukh T., Stephens, Deborah M., Ghia, Paolo, Barrientos, Jacqueline, Pagel, John M., Woyach, Jennifer A., Burke, Kathleen, Covey, Todd, Gulrajani, Michael, Hamdy, Ahmed, Izumi, Raquel, Frigault, Melanie M., Patel, Priti, Rothbaum, Wayne, Wang, Min Hui, O’Brien, Susan, Furman, Richard R.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2020
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7146022/
https://ncbi.nlm.nih.gov/pubmed/31876911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2018884940
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы